middle.news
How Tetratherix’s $3M US Deal Could Revolutionise Nasal Drug Delivery
8:32am on Monday 16th of March, 2026 AEDT
•
Healthcare
Read Story
How Tetratherix’s $3M US Deal Could Revolutionise Nasal Drug Delivery
8:32am on Monday 16th of March, 2026 AEDT
Key Points
Launch of precision medicine franchise using Tetramatrix™ platform
Exclusive 10-year R&D agreement with Superpower Health Inc
US$3 million annual licence fee plus polymer sales potential
Milestones on track with two FDA approvals expected mid-2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
TETRATHERIX (ASX:TTX)
OPEN ARTICLE